fiftyf
volunt
treat
either
intranas
recombin
interferon
rifn
x
ivday
placebo
day
expos
coronaviru
direct
intranas
inocul
eighth
day
treatment
symptom
score
record
cultur
viru
taken
daili
volunt
seven
day
inocul
nineteen
placebo
recipi
met
symptomscor
criteria
cold
compar
ifn
recipi
p
mean
nasal
symptom
score
placebo
ifn
group
respect
p
mean
total
symptom
score
two
group
respect
p
mean
number
day
total
symptom
score
placebo
recipi
rifn
recipi
p
prophylact
intranas
rifn
effect
shorten
durat
reduc
sever
coronaviru
cold
symptom
common
cold
occcur
averag
two
four
time
per
year
per
adult
six
time
per
year
per
child
recent
studi
examin
efficaci
interferon
prophylaxi
prevent
cold
famili
set
studi
indic
rhinoviru
cold
effect
prevent
effect
total
respiratori
ill
howev
less
impress
suggest
major
impact
incid
common
cold
requir
prevent
infect
caus
viral
pathogen
coronavirus
believ
respons
least
upperrespiratorytract
ill
although
inform
coronaviru
epidemiolog
limit
lack
reliabl
method
isol
viru
clinic
specimen
recent
report
suggest
sever
immunolog
distinct
strain
coronaviru
exist
capabl
caus
human
respiratori
tract
infect
infect
confer
protect
homolog
strain
viru
howev
durat
immun
known
exist
sever
viral
strain
uncertainti
possibl
reinfect
suggest
prevent
coronaviru
infect
activ
immun
difficult
previou
studi
observ
coronaviru
sensit
recombin
human
interferon
rifn
vitro
author
unpublish
observ
suggest
intranas
interferon
may
use
treat
prevent
coronaviru
cold
purpos
random
doubleblind
studi
determin
efficaci
rifn
prevent
coronaviru
cold
human
volunt
volunt
healthi
young
adult
volunt
recruit
univers
utah
individu
report
upperrespiratorytract
ill
preced
week
take
oral
intranas
medic
would
interfer
infect
assess
symptom
exclud
volunt
document
normal
complet
blood
cell
count
blood
chemistri
urinalysi
particip
studi
attempt
made
select
antibodyfre
volunt
studi
two
volunt
prechalleng
titer
antibodi
interferon
rifn
schere
kenilworth
nj
provid
lyophil
form
reconstitut
final
concentr
x
ium
placebo
ident
rifn
protein
content
ph
tonic
appear
also
provid
interferon
placebo
treatment
administ
nasal
spray
use
meter
pump
devic
deliv
ml
per
spray
nostril
spray
ml
medic
twice
day
viru
inoculum
pool
viru
inoculum
use
studi
coronaviru
strain
provid
dr
j
tyrrel
mrc
common
cold
unit
salisburi
england
inoculum
pool
consist
nasal
wash
human
volunt
coronaviru
cold
materi
test
presenc
pathogen
bacteria
dilut
earl
balanc
salt
solut
titer
tcidsoml
inocul
volunt
volunt
challeng
intranas
inocul
mlnostril
total
inoculum
rv
tcid
symptom
score
symptom
score
done
modif
previous
publish
method
volunt
ask
record
symptom
score
daili
studi
symptom
fever
chill
headach
muscl
ach
sneez
sore
throat
hoars
cough
nasal
symptom
rhinorrhea
nasal
obstruct
judg
absent
sever
assign
score
symptom
criteria
cold
total
symptom
score
least
addit
either
presenc
rhinorrhea
least
three
six
studi
day
coronaviru
inocul
subject
impress
volunt
cold
isol
ofviru
specimen
isol
viru
collect
daili
nasal
wash
seven
day
challeng
nostril
rins
ml
pb
mix
volvol
fourtim
concentr
beefheart
infus
broth
contain
fetal
calf
serum
antibiot
vancomycin
gentamicin
amphotericin
b
antibodi
ifn
suffici
neutral
iv
rifn
ad
millilit
sampl
incub
room
temperatur
least
min
ml
sampl
inocul
two
tube
cultur
human
embryon
lung
fibroblast
cell
maintain
eagl
mem
contain
fetal
calf
serum
one
tube
specimen
place
stationari
rack
roller
drum
tube
incub
c
tube
examin
ever
day
develop
cpe
tube
appar
cpe
passag
fresh
cell
observ
sampl
cpe
origin
tube
passag
consid
posit
coronaviru
isol
viru
confirm
coronaviru
elisa
nasal
wash
done
challeng
inocul
cynomolog
monkey
kidney
human
foreskin
fibroblast
mink
lung
cell
detect
unsuspect
virus
elisa
coronaviru
antigen
antiserum
coronaviru
produc
mice
guinea
pig
mous
antibodi
dilut
sodium
bicarbon
ph
adsorb
well
polystyren
microtit
plate
incub
overnight
c
v
nreact
bind
site
block
incub
plate
addit
hour
eaglesmem
contain
fetal
bovin
serum
rins
tap
water
j
li
uninfect
media
cell
cultur
supernat
coronaviru
isol
place
antibodyco
well
dilut
media
sampl
incub
hr
room
temperatur
plate
wash
three
time
tap
water
second
antibodi
guinea
pig
antibodi
ad
well
incub
hr
room
temperatur
wash
plate
tap
water
incub
third
antibodi
horseradish
peroxidaseconjug
rabbit
antibodi
guinea
pig
igg
cappel
laboratori
west
chester
pa
plate
hr
room
temperatur
plate
wash
tap
water
substrat
pb
ph
h
ad
well
incub
min
room
temperatur
absorb
measur
wavelength
nm
use
spectrophotomet
titertek
multiskan
flow
laboratori
mclean
va
specimen
consid
posit
absorb
sd
mean
absorb
neg
control
well
serolog
assay
neutral
antibodi
done
microtit
plate
serial
twofold
dilut
serum
incub
tcid
coronaviru
five
day
c
well
examin
cpe
titer
neutral
antibodi
calcul
volunt
consid
infect
least
fourfold
increas
titer
neutral
antibodi
cours
studi
studi
design
assign
treatment
group
done
randomli
doubleblind
volunt
investig
volunt
treat
intranas
rifn
iv
twice
day
placebo
one
week
challeng
studi
viru
day
challeng
one
week
challeng
thu
treat
volunt
receiv
total
x
iv
rifn
day
volunt
indic
dose
taken
mark
form
time
medic
administ
form
check
studi
staff
time
volunt
seen
symptom
score
monitor
begin
first
day
rifn
placebo
treatment
continu
three
week
eighth
day
interferon
placebo
treatment
volunt
challeng
studi
viru
nasal
wash
detect
shed
viru
collect
seven
day
begin
day
challeng
statist
analysi
proport
compar
onesid
fisher
exact
test
symptom
score
two
group
recipi
compar
twosid
mannwhitney
u
test
twentyseven
volunt
receiv
placebo
twentynin
receiv
rifn
one
placebo
recipi
report
symptom
score
day
coronaviru
inocul
exclud
data
analysi
effect
rifn
symptom
use
rifn
significantli
reduc
symptom
coronaviru
cold
tabl
nineteen
placebo
recipi
met
symptomscor
criteria
cold
compar
rifn
recipi
p
mean
nasal
symptom
score
six
day
challeng
placebo
recipi
rifn
recipi
p
total
symptom
score
two
group
respect
p
mean
number
day
total
symptom
score
seroconvert
lower
initi
titer
four
volunt
initi
titer
least
fourfold
increas
antibodi
titer
compar
volunt
initi
titer
p
convalesc
sera
avail
three
volunt
presenc
antibodi
acut
serum
specimen
discern
effect
rate
isol
viru
symptom
score
side
effect
ofrifn
five
placebo
rifn
recepi
report
bloodi
nasal
mucu
least
day
studi
four
placebo
recipi
six
rifn
recipi
report
bloodi
nasal
mucu
first
week
observ
inocul
coronaviru
differ
statist
signific
also
differ
nasal
total
symptom
score
two
group
challeng
nasal
speculum
examin
done
day
reveal
mucos
ulcer
either
treatment
group
howev
bleed
site
seen
eight
rifn
recipi
one
placebo
recipi
p
abnorm
blood
count
blood
chemistri
urinalys
could
attribut
rifn
treatment
seen
volunt
withdrew
studi
due
side
effect
interferon
placebo
treatment
result
studi
indic
prophylact
intranas
rifn
dose
x
iuday
effect
reduc
durat
sever
coronaviru
cold
benefici
effect
symptom
howev
associ
decreas
incid
infect
previou
studi
higgin
et
al
gave
x
iu
intranas
interferonday
volunt
begin
one
day
turner
et
al
coronaviru
challeng
studi
infect
ill
reduc
interferontr
group
abil
interferon
modifi
ill
dose
prevent
infect
also
report
studi
rhinoviru
infect
sarno
et
al
report
x
iu
interferon
daili
modifi
rhinoviru
ill
affect
rate
viral
infect
higher
daili
dose
interferon
howev
ill
infect
significantli
reduc
mechan
symptom
reduc
interferon
without
associ
reduct
infect
known
attempt
made
inthi
studi
quantifi
amount
viru
shed
nasal
secret
determin
effect
interferon
host
respons
viru
either
factor
may
import
product
symptom
respiratori
viral
infect
studi
human
coronavirus
hamper
difficulti
isol
viru
clinic
specimen
studi
placebotr
volunt
viru
isol
nasal
wash
specimen
unlik
mani
virus
coronavirus
produc
distinct
cpe
cell
cultur
reliabl
distinguish
nonspecif
cytotox
assur
specif
cell
cultur
isol
routin
passag
cultur
appar
coronaviru
cpe
fresh
cell
specimen
produc
cpe
consid
posit
coronaviru
data
analyz
posit
cultur
confirm
coronaviru
elisa
evid
specif
isol
viru
support
fact
volunt
viru
isol
also
fourfold
increas
titer
neutral
antibodi
viru
patient
signific
rise
titer
neutral
antibodi
nine
initi
titer
two
convalesc
sera
avail
analysi
invers
relat
frequenc
seroconvers
level
preexist
antibodi
coronaviru
previous
report
interest
import
featur
coronaviru
epidemiolog
abil
viru
infect
produc
symptom
associ
shed
viru
spite
presenc
preexist
neutral
antibodi
presenc
high
titer
antibodi
effect
either
ill
infect
studi
volunt
high
initi
titer
antibodi
less
like
fourfold
rise
titer
effect
previous
report
reed
recent
report
strain
differ
within
serogroup
infect
may
provid
protect
immun
homolog
strain
heterolog
strain
role
intranas
rifn
therapi
play
prevent
treatment
coronaviru
cold
remain
determin
regimen
studi
prevent
cold
includ
prophylaxi
epidem
period
contact
prophylaxi
home
lack
inform
coronaviru
epidemiolog
make
difficult
predict
either
regimen
practic
prevent
coronaviru
infect
also
known
whether
rifn
effect
treat
coronaviru
cold
studi
address
issu
practic
dose
regimen
prevent
treat
common
cold
need
rifn
use
clinic
set
